Royal London Asset Management Ltd. Has $6.86 Million Stake in Natera, Inc. $NTRA

Royal London Asset Management Ltd. grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 7.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,287 shares of the medical research company’s stock after purchasing an additional 1,813 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Natera were worth $6,864,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the period. BlackRock Inc. bought a new position in Natera in the second quarter worth approximately $2,962,770,000. Wellington Management Group LLP boosted its holdings in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp grew its stake in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after acquiring an additional 72,087 shares during the period. Finally, Coatue Management LLC grew its stake in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NTRA opened at $321.96 on Tuesday. The company has a market capitalization of $46.41 billion, a price-to-earnings ratio of -236.73 and a beta of 1.51. The firm’s fifty day moving average price is $286.93 and its two-hundred day moving average price is $234.55. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $343.18.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the company posted ($0.74) earnings per share. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. As a group, equities analysts anticipate that Natera, Inc. will post -1.02 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NTRA. BTIG Research upped their target price on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $315.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Royal Bank Of Canada boosted their price target on shares of Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Guggenheim raised their price target on shares of Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the transaction, the insider owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider owned 197,257 shares in the company, valued at approximately $63,424,043.21. The trade was a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 103,472 shares of company stock valued at $24,960,134. 5.05% of the stock is currently owned by company insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.